Form 4: Relay Therapeutics CFO Granted 400,000 Stock Options

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, was granted 400,000 stock options with an exercise price of $7.94, vesting quarterly over four years.

Summary

• Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc. (RLAY), was granted 400,000 stock options.
• The stock options have an exercise price of $7.94 per share.
• The grant date for these options was January 13, 2026.
• The options will vest in sixteen equal quarterly installments after January 13, 2026, contingent on the reporting person's continued service with the Issuer.
• The expiration date for these stock options is January 12, 2036.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive event, signaling confidence in the company's future and aligning management's interests with shareholders. The long vesting period promotes retention. The potential for future dilution is a minor negative, typical of such compensation.

Positives

• The grant of 400,000 stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders.
• The vesting schedule over four years (16 quarterly installments) acts as a retention mechanism for a key executive.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if exercised.

Risks

• The vesting of the stock options is subject to the reporting person's continued service with Relay Therapeutics, Inc. through each vesting date.

Future Outlook

The stock option grant incentivizes the Chief Financial Officer to contribute to the company's long-term growth and share price appreciation, aligning future executive performance with shareholder value.

Industry Context

The grant of stock options to a key executive like the CFO is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize top talent, linking their compensation to the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common executive compensation tool across the biotech sector, comparable to practices at companies like Moderna or BioNTech, aiming to align executive incentives with long-term shareholder returns.
• The exercise price being set at the market price on the grant date (implied by the $0.00 price of derivative security and $7.94 exercise price) is typical for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized management; minor potential for future dilution from option exercise.
• Employees: Signals stability in executive leadership and a commitment to long-term incentives.
• Management: Direct financial incentive tied to the company's stock performance and continued employment.

Next Steps

• Continued service of the CFO with the Issuer for the options to vest.
• Future exercise of options by the CFO, subject to vesting and market conditions.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event, specifically a stock option grant to the Chief Financial Officer. While it aligns management incentives with shareholder interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Relay Therapeutics, RLAY, Stock Options, CFO, Executive Compensation, Form 4, Insider Transaction, Equity Grant